Oberon Uranium Corp. (OBRN.CN)
CAD 0.01
(100.0%)
CAD 0.01
(100.0%)
| Breakdown | 2024 | 2023 |
|---|---|---|
| Revenue | - | - |
| Cost of Revenue | - | - |
| Gross Profit | - | - |
| Operating Expenses | 375.21 Thousand | 748.58 Thousand |
| Selling, General and Administrative Expenses | 375.21 Thousand | 748.58 Thousand |
| Research and Development Expenses | - | - |
| Other Expenses | - | - |
| Cost and Expenses | 375.21 Thousand | 748.58 Thousand |
| Operating Income | -375.21 Thousand | -749.63 Thousand |
| Interest Expense | 1109.00 | 1050.00 |
| Income Tax Expense | -388.56 Thousand | -227.43 Thousand |
| Earnings before Tax | -388.56 Thousand | -759.08 Thousand |
| Net Income | -388.56 Thousand | -759.08 Thousand |
| Earnings Per Share Basic | -0.01 | -0.03 |
| Earnings Per Share Diluted | -0.01 | -0.03 |
| Weighted Average Shares Outstanding | 44.02 Million | 23.42 Million |
| Weighted Average Shares Outstanding (Diluted) | 44.02 Million | 23.42 Million |
| Gross Margin | - | - |
| EBIT Margin | - | - |
| Profit Margin | - | - |
| EBITDA | -387.46 Thousand | -748.58 Thousand |
| Earnings Before Tax Margin | - | - |
| Breakdown | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| Operating Expenses | 75.74 Thousand | 375.21 Thousand | 33.08 Thousand | 80.31 Thousand | 122.39 Thousand | 139.41 Thousand |
| Selling, General and Administrative Expenses | 75.74 Thousand | - | 33.08 Thousand | 80.31 Thousand | 112.92 Thousand | 138.4 Thousand |
| Research and Development Expenses | - | - | - | - | - | - |
| Other Expenses | 22.43 Thousand | - | - | - | - | - |
| Cost and Expenses | 75.74 Thousand | 375.21 Thousand | 33.08 Thousand | 80.31 Thousand | 122.39 Thousand | 139.41 Thousand |
| Operating Income | -75.74 Thousand | -375.21 Thousand | -33.08 Thousand | -80.32 Thousand | -122.7 Thousand | -139.67 Thousand |
| Interest Expense | 246.00 | 1109.00 | 270.00 | 268.00 | 312.00 | 259.00 |
| Income Tax Expense | - | - | - | 39.58 Thousand | -312.00 | -41.32 Thousand |
| Earnings before Tax | -16.21 Thousand | -388.56 Thousand | -44.85 Thousand | -80.58 Thousand | -122.7 Thousand | -140.42 Thousand |
| Net Income | -16.21 Thousand | -388.56 Thousand | -44.85 Thousand | -80.58 Thousand | -122.7 Thousand | -140.42 Thousand |
| Earnings Per Share Basic | -0.00 | - | -0.00 | -0.00 | -0.00 | -0.00 |
| Earnings Per Share Diluted | -0.00 | - | -0.00 | -0.00 | -0.00 | -0.00 |
| Weighted Average Shares Outstanding | 60.66 Million | 44.02 Million | 44.93 Million | 44.68 Million | 44.68 Million | 42.04 Million |
| Weighted Average Shares Outstanding (Diluted) | 60.66 Million | 44.02 Million | 44.93 Million | 44.68 Million | 44.68 Million | 42.04 Million |
| Gross Margin | - | - | - | - | - | - |
| EBIT Margin | - | - | - | - | - | - |
| Profit Margin | - | - | - | - | - | - |
| EBITDA | -75.74 Thousand | - | -33.08 Thousand | -80.32 Thousand | -122.39 Thousand | -139.41 Thousand |
| Earnings Before Tax Margin | - | - | - | - | - | - |
BGBIO
TD-PFA
KOG
CFF
688659
IR5B